Rethinking Dose Optimization: Aligning with FDA’s Project Optimus – IQVIA Research and Development Solutions
IQVIA Research and Development Solutions shared an event on LinkedIn:
“Rethinking dose optimization in oncology trials.
Join experts from IQVIA and Sarah Cannon Research Institute on August 14 for a strategic discussion on how teams can move beyond the traditional maximum tolerated dose (MTD) paradigm to embrace innovative, model-informed strategies that align with FDA’s Project Optimus. Don’t miss it – register today!”
Sarah Cannon Research Institute shared this post, adding:
“On August 14, join leading experts from IQVIA and Sarah Cannon Research Institute as they engage in a for a forward-thinking discussion on transforming dose selection in oncology trials.
Discover how innovative trial design can improve patient outcomes and accelerate drug development.
Don’t miss this important conversation – Register now!”
More posts featuring IQVIA and Sarah Cannon Research Institute.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023